Thrombotic Microangiopathy After Renal Transplantation in the United States

American Journal of Kidney Diseases

Volumn 42, Issue 5, 2003, Pages 1058-1068

  Reynolds, Joel C ^b   Agodoa, Lawrence Y ^b   Yuan, Christina M ^b   Abbott, Kevin C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Age; Calcineurin inhibitor; Complications; Cyclosporine; Hemolytic uremic syndrome (HUS): thrombotic thrombocytopenic purpura; Immunosuppression; Recurrence; Sirolimus; Tacrolimus; Thrombotic microangiopathy (TMA); United States Renal Data System (USRDS)

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN;

ADULT; AGING; ARTICLE; DATA BASE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORGAN TRANSPLANTATION; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; UNITED STATES RENAL DATA SYSTEM;

EID: 0142250921     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajkd.2003.07.008     Document Type: Article

References (47)

1. Moake JL: Thrombotic microangiopathies. N Engl J Med 347:589-600, 2002
2. Tsai HM: Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura. Int J Hematol 76:132-138, 2002 (suppl 2)
3. Nissenson AR, Port FK: Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. Q J Med 74:63-74, 1990
4. Hollenbeck M, Kutkuhn B, Aul C, et al: Haemolyticuraemic syndrome and thrombotic-thrombocytopenic purpura in adults: Clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 13:76-81, 1998
5. Young BA, Marsh CL, Alpers CE, Davis CL: Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 28:561-571, 1996
6. Wiener Y, Nakhleh RE, Lee MW, et al: Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant 11:157-162, 1997
7. Zent R, Katz A, Quaggin S, et al: Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol 47:181-186, 1997
8. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55:2457-2466, 1999
9. Langer RM, Van Buren CT, Katz SM, Kahan BD: De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 73:756-60, 2002
10. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS: De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41:471-479, 2003
11. Chiurchiu C, Ruggenenti P, Remuzzi G: Thrombotic microangiopathy in renal transplantation. Ann Transplant 7:28-33, 2002
12. Ducloux D, Rebibou JM, Semhoun-Ducloux S, et al: Recurrence of hemolytic-uremic syndrome in renal transplant recipients: A meta-analysis. Transplantation 65:1405-1407, 1998
13. Quan A, Sullivan EK, Alexander SR: Recurrence of hemolytic uremic syndrome after renal transplantation in children: A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 72:742-745, 2001
14. Ferraris JR, Ramirez JA, Ruiz S, et al: Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 17:809-814, 2002
15. Ruggenenti P, Remuzzi G: Thrombotic microangiopathies. Crit Rev Oncol Hematol 11:243-265, 1991
16. Docci D, Baldrati L, Capponcini C, Facchini F, Giudicissi A, Feletti C: Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in a patient with Behcet's disease treated with cyclosporin. Nephron 75:356-357, 1997
17. Saikali JA, Truong LD, Suki WN: Sirolimus may promote thrombotic microangiopathy. Am J Transplant 3:229-230, 2003
18. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D: Thrombotic micro-angiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3:324-327, 2003
19. Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N: Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 42:202-206, 2003
20. Hariharan S, Adams MB, Brennan DC, et al: Recurrent and de novo glomerular disease after renal transplantation: A report from Renal Allograft Disease Registry (RADR). Transplantation 68:635-641, 1999
21. Bleyer AJ, Donaldson LA, McIntosh M, Adams PL: Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 37:1152-1161, 2001
22. Waiser J, Budde K, Rudolph B, Ortner MA, Neumayer HH: De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis 34:556-559, 1999
23. Langer RM, Van Buren CT, Katz SM, Kahan BD: De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 73:756-760, 2002
24. Donne RL, Abbs I, Barany P, et al: Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 40:E22, 2002
25. Bucci JR, Matsumoto CS, Swanson SJ, et al: Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 13:2974-2982, 2002
26. Abbott KC, Oglesby RJ, Agodoa LY: Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int 62:2250-2256, 2002
27. http://www.cdc.gov/nchs/
28. Kaufman HM, McBride MA, Rosendale JD, Ellison MD, Daily OP, Wolf JS: Trends in organ donation. Recovery and disposition: UNOS Data for 1988-1996. Transplant Proc 29:3303-3304, 1997
29. Fuge R, Bird JM, Fraser A, et al: The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 113:58-64, 2001
30. Ruutu T, Hermans J, Niederwieser D, et al: Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: A survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118:1112-1119, 2002
31. Torok TJ, Holman RC, Chorba TL: Increasing mortality from thrombotic thrombocytopenic purpura in the United States - Analysis of national mortality data, 1968-1991. Am J Hematol 50:84-90, 1995
32. Edwards C, House A, Shahinian V, Knoll G: Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 17:1524-1526, 2002
33. Young BA, Marsh CL, Alpers CE, Davis CL: Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 28:561-571, 1996
34. Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN: FK506-associated thrombotic microangiopathy: Report of two cases and review of the literature. Transplantation 67:539-544, 1999
35. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, et al: Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 43:78-84, 2003
36. Agarwal DK, Gulati S, Mehta A, et al: Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome. Nephrol Dial Transplant 15:2064-2065, 2000
37. Szklo M, Nieto FJ: Epidemiology Beyond the Basics. Identifying Non-Causal Associations: Confounding. Gaithersburg, MD, Aspen Publishers, 2000, p 177
38. Agarwal A, Mauer SM, Matas AJ, Nath KA: Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management. J Am Soc Nephrol 6:1160-1169, 1995
39. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55:2457-2466, 1999
40. Abraham KA, Little MA, Dorman AM, Walshe JJ: Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 13:443-447, 2000
41. Heering P, Deppe CE, Farokhzad F, Helmchen U, Grabensee B: Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with rapamycin. Nephron 91:177, 2002 (letter)
42. Macdonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporin regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. The Rapamune Global Study Group. Transplantation 71:271-280, 2001
43. Benito AI, Furlong T, Majtin PJ, et al: Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924-1929, 2001
44. Rick ME, Moll S, Taylor MA, Krizek DM, White II GC, Aronson DL: Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 88:598-604, 2002
45. Pham PT, Danovitch GM, Wilkinson AH, et al: Inhibitors of ADAMTS13: A potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 74:1077-1080, 2002
46. Vesely SK, George JN, Lammle B, et al: ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102:60-68, 2003
47. Lahlou A, Lang P, Charpentier B, et al: Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de l'Ile-de-France (GCIF). Medicine (Baltimore) 79:90, 2000